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The use of E. coli purine nucleoside phosphorylase (PNP) to activate prodrugs has demonstrated excellent activity in the treatment
of various human tumor xenografts in mice. E. coli PNP cleaves purine nucleoside analogs to generate toxic adenine analogs, which
are activated by adenine phosphoribosyl transferase (APRT) to metabolites that inhibit RNA and protein synthesis. We created tumor
cell lines that encode both E. coli PNP and excess levels of human APRT, and have used these new cell models to test the hypo-
thesis that treatment of otherwise refractory human tumors could be enhanced by overexpression of APRT. In vivo studies
with 6-methylpurine-20-deoxyriboside (MeP-dR), 2-F-20-deoxyadenosine (F-dAdo) or 9-b-D-arabinofuranosyl-2-fluoroadenine
50-monophosphate (F-araAMP) indicated that increased APRT in human tumor cells coexpressing E. coli PNP did not enhance either
the activation or the anti-tumor activity of any of the three prodrugs. Interestingly, expression of excess APRT in bystander cells
improved the activity of MeP-dR, but diminished the activity of F-araAMP. In vitro studies indicated that increasing the expression of
APRT in the cells did not significantly increase the activation of MeP. These results provide insight into the mechanism of bystander
killing of the E. coli PNP strategy, and suggest ways to enhance the approach that are independent of APRT.
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Introduction
The use of E. coli purine nucleoside phosphorylase (PNP)
to activate deoxyadenosine (dAdo) analogs has demon-
strated impressive efficacy against numerous human
tumor xenografts in mice.
1–6 This strategy differs funda-
mentally from earlier generation suicide gene approaches
such as those utilizing herpes simplex virus-thymidine
kinase or E. coli cytosine deaminase because of its unique
mechanism of action and its robust bystander activity. To
date, three prodrugs have been used in combination with
E. coli PNP (6-methylpurine-20-deoxyriboside (MeP-dR);
2-F-20-dAdo (F-dAdo) and arabinofuranosyl-2-F-adenine
monophosphate (F-araAMP, fludarabine phosphate)).
These dAdo analogs are not activated in normal human
tissues, because human PNP does not recognize adenine-
containing nucleosides or their analogs as substrates.
F-araAMP is of particular interest as a prodrug, because
it is currently approved for use in the treatment of chronic
lymphocytic leukemia, and has demonstrated excellent in
vivo anti-tumor activity even when 97.5% of tumor cells
do not express E. coli PNP.
3 F-araAMP is used in in vivo
studies as a more soluble precursor of F-araA. In the
plasma it is quickly converted to F-araA, which is the
primary circulating form of the drug
7,8 and a substrate for
E. coli PNP.
E. coli PNP cleaves the glycosidic bond of these
dAdo analogs liberating either (MeP) or 2-fluoroadenine
(F-Ade), two potent cytotoxic adenine analogs.
9 Both
MeP and F-Ade readily diffuse across cell membranes and
kill neighboring tumor cells that do not express E. coli
PNP,
10,11 accounting for the robust bystander activity
observed with this strategy. In human cells adenine is
salvaged from the extracellular environment by adenine
phosphoribosyl transferase (APRT), and this enzyme is
responsible for the first and rate-limiting step in the
activation of both MeP and F-Ade. Once monopho-
sphates of MeP or F-Ade have been formed, they are
rapidly converted by cellular mono and diphosphate
kinases to their respective triphosphates (MeP-riboside-
TP and F-ATP), which inhibit both RNA and protein
synthesis.
9 Because of the unique mechanism of action,
these two agents are active against non-proliferating
tumor cells, an attribute that could be quite useful in the
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Furthermore, these agents should also be active against
the putative tumor ‘stem cell’ compartment, which is
constituted of cells that spend a substantial interval of
time in a quiescent state (a factor that contributes to
tumor growth and regeneration after treatment with
conventional chemotherapy).
Although excellent in vivo anti-tumor activity has been
observed with three prodrugs, the amount of E. coli PNP
enzyme activity in tumor cells transfected with the E. coli
PNP gene is much greater than the endogenous APRT
activity. Therefore, it is possible that MeP and F-Ade
produced by E. coli PNP are not efficiently activated by
APRT, but instead diffuse away from the tumor. There-
fore, to determine whether or not additional APRT
activity in tumor cells that express E. coli PNP would
improve the anti-tumor effectiveness of these prodrugs,
we established tumor cell lines that encode both E. coli
PNP and excess levels of human APRT, and have used
these new cell models to test the hypothesis that treatment
of otherwise refractory human tumors could be enhanced
by overexpressing APRT.
Materials and methods
Cloning of APRT
The APRT gene was amplified from HeLa complimentary
DNA pool using AccuPrime Pfx Supermix (Invitrogen;
Carlsbad, CA), according to manufacturer’s protocol.
The sequences of PCR primers used were APRT-f: 50-
AGCTGGATCCACCATGGCCGACTCCGAGCTG-30
and APRT-r: 50-ACCTCTCGAGTCACTCATACTGCA
GGAGAGAGAA-30. The amplified PCR product was
cloned into pCR4-Blunt (Invitrogen) vector and con-
firmed by DNA sequencing. The APRT gene was cloned
into the PmeI site of pWPI lentiviral vector (Addgene,
Cambridge, MA). The pWPI vector encodes green fluor-
escent protein downstream of cloning sites and an internal
ribosome entry site allowing coexpression of green fluor-
escent protein together with the cloned gene of interest.
Creation of D54 cells expressing excess levels of APRT
D54MG cells were obtained from Yancey Gillespie,
University of Alabama, Birmingham
12 and grown in
RPMI 1640 medium (Gibco-BRL, Gaithersburg, MD)
containing 10% fetal bovine serum (Gibco-BRL), 10Uml
penicillin, 10mgml
 1 streptomycin and 50mgml
 1 genta-
mycin. To produce a lentiviral vector, 40mg of plasmid
DNA was used for calcium-phosphate transfection of one
10cm dish. The DNA mixture contained 5mg of envelope-
coding plasmid pMD.G; 15mg of the packaging plasmid
pCMVdR8.91, which expresses Gag, Pol, Tat and Rev;
and 20mg of pWPI-APRTase. The tissue culture media
was collected and used to infect cells. Twenty-four hours
after lentiviral infection, the cells were split into 96-well
plates for cloning a homogenous population with APRT
expression. Cell clones were visually inspected for green
fluorescent protein expression. A final round of clonal
isolation was performed to ensure the homogeneity of
each cell population. Cells were analyzed for APRT
activity to confirm the expression of the enzyme.
Measurement of PNP and APRT activity
Crude cell extracts were prepared as described previously
from D54MG (human glioma) cells in culture
13 and from
D54MG tumors removed from the flanks of mice.
2 Cell
extract was incubated with 50mM potassium phosphate,
100mM MeP-dR and 100mM 4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid buffer (pH 7.4) to obtain a linear
reaction over the incubation period. The formation of
MeP was monitored using reverse phase high pressure
liquid chromatography. One unit of PNP activity is equal
to the amount of extract that can cleave 1nmole of MeP-
dR per mg protein in a 1-h period.
To measure APRT activity the extracts prepared
above were incubated with 100mM [2,8-
3H]adenine
(2000Cimole
 1, from Moravek Biochemicals; Brea,
CA), 1mM phosphoribosyl pyrophosphate, 5mM MgCl2
and 50mM Tris (pH 7.4). A portion of the extract was
applied to DE81 anion exchange disks (Whatman
International, Maidstone, England) at various times after
starting the reaction. The [
3H]adenine was removed by
washing the disks three times with 1mM ammonium
formate solution and twice with 95% ethanol. After
drying, the amount of [
3H]AMP formed was determined
by counting the radioactivity left on the DE81 disks.
Studies with human tumor xenografts in mice
Mixtures of D54MG tumor cells expressing E. coli PNP
and/or human APRT (2 10
7 cells) were injected
subcutaneously into the flanks of nude mice (nu/nu)
purchased from Charles River Laboratories (Wilmington,
MA). Tumors were measured with calipers and an
estimate of the weight was calculated using the equation,
(length width
2)/2¼mm
3, which is converted to mg
assuming unit density.
14 The proportions of transduced
tumor cells were verified by measuring E. coli PNP
activity in representative tumors removed from the mice
on the first day of drug treatment. When tumors reached
approximately 300mg, the mice were treated intraper-
itoneally with MeP-dR, F-dAdo or F-araAMP at
maximally tolerated doses. F-dAdo was administered at
a dose of 20mgkg
 1 five times a day (separated by 2h)
for 3 consecutive days (Q1Dx3-Q2Hx5). MeP-dR was
administered at a dose of either 33 or 67mgkg
 1 once per
day for 3 consecutive days (Q1Dx3). F-araAMP was
administered at a dose of 160mgkg
 1 given three times a
day (separated by 4h) for 3 consecutive days (Q1Dx3-
Q4Hx3), except in Figure 2 where it was administered at
a dose of 100mgkg
 1 five times a day (separated by 2h)
for 3 consecutive days. There were six mice per treatment
group. MeP-dR was synthesized in our laboratories
as described previously.
15 F-araAMP was obtained
from Schering AG (Berlin, Germany) and F-dAdo
was obtained from General Intermediates of Canada
(Edmonton, Alberta, Canada). Mice were monitored
daily and were evaluated for weight loss and tumor
mass twice weekly. T-C (tumor growth delay) is the
difference in days to 2 doublings between drug-treated
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in a Student’s t-test, the Mann–Whitney rank sum test or
a life table analysis in order to statistically compare
growth data between treatment groups. All procedures
were performed in accordance with a protocol that was
approved by the Institutional Animal Care and Use
Committee of Southern Research Institute.
Total radioactivity in tumors was determined after
intraperitoneal injection of 20mgkg
 1 [8-
3H]F-dAdo
(6.7Cimole
 1), 100mgkg
 1 [8-
3H]F-araAMP (1.4Cimole
 1)
or 33mgkg
 1 [2,8-
3H]MeP-dR (3.8Cimole
 1) into mice
bearing D54 tumors of approximately 300mg. Prodrugs
labeled with tritium were obtained from Moravek
Biochemicals. Tumors were removed from the mice 4h
after injection of compound and were dissolved in 1ml of
Soluene 350 (Packard Instrument, Meriden, CT) by
incubating at 551C for 4h and then at room temperature.
A portion of each extract was mixed with scintillation
fluid and the radioactivity was determined.
Results
Creation of D54 cells expressing excess APRT activity
We have expressed E. coli PNP in D54 cells (D54/PNP) at
very high levels (126000nmol per mg per h) and used these
cells to evaluate the use of E. coli PNP to activate F-araA as
a therapy for the treatment of cancer.
3 The endogenous
specific activity of APRT in this cell line was determined to
be approximately 87nmol of adenine activated per mg per
cellular protein per h, which is 1400-fold lower than the
E. coli PNP activity in these cells. Because APRT is the first
enzyme in the activation pathway for adenine analogs
generated by E. coli PNP and its activity appeared limiting
in these cells, we established D54 cell lines that stably express
human APRT and determined whether increased expression
of APRT in cells expressing E. coli PNP would enhance cell
killing activity of F-araA, F-dAdo or MeP-dR. D54/PNP
cells were transduced with the human APRT gene resulting
in a cell line (D54/PNP/APRT) that stably expresses both
E. coli PNP (159000nmol per mg per h) and excess human
APRT activity (6000nmol per mg per h). Wild-type D54
cells were also transfected with the human APRT gene
resulting in a cell line (D54/APRT) that stably expresses
excess APRT activity (17000nmol per mg per h). The
differences in expression levels of E. coli PNP and human
APRT in the various cell lines are expected, based on the
variable genomic integration sites of a particular lentiviral
vector, the number of tandem repeats at the site of
integration, partial cellular repression of transcription and
other factors. D54 clones were selected that had similar
activities for comparison. The in vitro and in vivo rates of
proliferation of both of these cell lines were similar to that
seen in wild-type D54 and D54/PNP cells.
In vivo anti-tumor activity of MeP-dR, F-dAdo or
F-araAMP against tumors that express excess APRT
activity
In previous studies, we demonstrated excellent in vivo
anti-tumor activity with F-araAMP against D54 tumors
in which all cells expressed E. coli PNP.
3 To evaluate
in vivo bystander activity of MeP-dR, F-dAdo and
F-araAMP, mice bearing D54 tumors in which 10% of
the cells expressed E. coli PNP were treated with the three
prodrugs at maximally tolerated doses. Treatment with
F-araAMP cured mice of D54 tumors in which 10% of
the cells expressed E. coli PNP, whereas treatment with
either F-dAdo or MeP-dR had a modest affect on the
growth of these tumors. In the experiment shown in
Figure 1, the amount of MeP-dR that could be tolerated
by the mice bearing tumors expressing E. coli PNP was
decreased, indicating that a substantial amount of the
MeP produced in these tumors was released into the
systemic circulation. Unlike MeP-dR, the toxicity of
F-dAdo or F-araAMP was not affected by expression of
E. coli PNP in the tumor xenografts, which suggested that
little or no F-Ade escaped from tumor tissues after
treatment with these agents. The toxicity of F-dAdo or
F-araAMP was not affected even when mice bearing
tumors in which 100% of the cells expressed E. coli PNP
at high levels (data not shown) were treated with these
two agents at their maximally tolerated doses. The three
prodrugs had no in vivo anti-tumor activity against D54
tumors that do not express E. coli PNP (Figure 2).
Although both F-dAdo and F-araAMP are known to
inhibit the growth of parental D54 tumor cells in vitro due
to their conversion to dATP analogs and subsequent
Figure 1 Effect of prodrugs on tumors that express E. coli PNP
(purine nucleoside phosphorylase) in 10% of the cells. Wild-type D54
tumor cells were mixed with D54 tumor cells that had been
transduced with the E. coli PNP gene, so that 10% of the mixture
contained cells that expressed E. coli PNP. This 90/10 mixture
was injected subcutaneously into the flanks of nude mice. Drug
treatment began on day 14 when tumors were approximately
300mg. The activity of E. coli PNP and human adenine phosphor-
ibosyl transferase in the tumors at the time of treatment were
11200±2300 units and 87±30 units, respectively. In F-araAMP-
treated mice on day 66 there was one complete regression, two
small non-growing tumors and three small (o500mg) but growing
tumors. The growth of tumors in mice treated with drugs was
significantly different than that in vehicle treated animals;
P valuesp0.001 in all cases. The experiment has been repeated
with similar results.
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16 these results indicated that
in vivo activation of both drugs by endogenous nucleoside
kinases is not sufficient to have an effect on the growth of
parental D54 tumors. In Figure 2 the same total amount
of F-araAMP was administered to the mice as in the other
in vivo experiments, but the schedule of administration
was slightly different (five times per day vs three times per
day). Similar negative results have been seen in experi-
ments where 160mgkg
 1 of F-araAMP (Q1Dx3-Q4Hx3)
was administered to mice bearing parental D54 tumors
(data not shown).
To determine the effect of excess APRT expression on
in vivo bystander activity, the D54/PNP/APRT cell line
was mixed with parental D54 cells and injected into mice
to establish xenografts in which 10% of the cells expressed
both E. coli PNP and excess APRT activity. The
effectiveness of F-dAdo, MeP-dR and F-araAMP against
these tumors (Figure 3) was similar to the effectiveness of
these same drugs against D54 xenografts in which 10% of
the tumor cells only expressed E. coli PNP (Figure 1).
Since treatment with F-araAMP was very active against
D54 tumors in which 10% of the cells expressed E. coli
PNP (Figure 1), it was not possible to determine from the
experiment shown in Figure 3 whether F-araAMP was
more effective against D54 tumors in which 10% of
the cells expressed both E. coli PNP and excess APRT.
Therefore, mice bearing tumors in which 10% of the
cells were either D54/PNP or D54/PNP/APRT were
treated with 50mgkg
 1 F-araAMP (Figure 4), which was
approximately 30% of the dose used in Figure 3. At this
dose, F-araAMP had a small effect on the growth of
both tumor models (T-C values of 7–10 days). Another
experiment was also performed to determine the influence
of F-dAdo or F-araAMP at dose and schedules used in
Figure 3 against D54 tumor xenografts, in which 2.5% of
the cells expressed either E. coli PNP or E. coli PNP
plus excess APRT (data not shown). We observed that
F-dAdo had no anti-tumor activity against either tumor,
and F-araAMP demonstrated similar, but modest,
activity against both tumor models (T-C values of
approximately 10 days). These results indicate that
increased expression of APRT in cells expressing E. coli
PNP activity does not enhance the anti-tumor activity of
MeP-dR, F-dAdo or F-araAMP.
In order to investigate the mechanisms underlying
bystander killing by E. coli PNP, tumors were established
in which the bystander cells expressed excess levels of
APRT. Dramatic differences in the anti-tumor activity of
MeP-dR and F-araAMP were seen in tumors in which
10% of the cells expressed E. coli PNP, and all the
bystander cells expressed excess APRT activity (Figure 5).
Treatment with MeP-dR was much more effective against
these tumors than it was against tumors that did not
express excess APRT in the bystander cells (Figure 1).
This result suggested that the increased expression of
APRT in the bystander cells enhanced the ability of these
cells to activate MeP to toxic metabolites. The expression
of excess APRT activity in either the E. coli PNP-
expressing cells (Figure 3) or the bystander cells (Figure 5)
did not reduce the toxicity of MeP-dR, which indicated
Figure 3 Effect of prodrugs on tumors that express both E. coli
PNP (purine nucleoside phosphorylase) and excess human APRT
(adenine phosphoribosyl transferase) in 10% of the cells. Wild-type
D54 tumor cells were mixed with D54 tumor cells that had been
transduced with both the E. coli PNP gene and the human APRT
gene so that 10% of the mixture contained cells that expressed
E. coli PNP and excess levels of human APRT. This 90/10 mixture
was injected subcutaneously into the flanks of nude mice. Drug
treatment began on day 15 when tumors were approximately
300mg. The activity of E. coli PNP and human APRT in the tumors
at the time of treatment were 14100±550 units and 173±45 units,
respectively. In 6-methylpurine-20-deoxyriboside-treated mice on day
59 there were six growing tumors (405–1800mg). In F-araAMP-
treated mice on day 59 there was one complete regression, two
small non-growing tumors (48 and 88mg) and three growing tumors
(486, 608, 1029mg). The growth of tumors in mice treated with
drugs was significantly different than that in vehicle treated animals;
P values 0.001 in all cases. The experiment has been repeated with
similar results.
Figure 2 Effect of prodrugs on D54 tumors that express EGFR.
The D54 tumors cells that had been transduced with the EGFR gene
were injected subcutaneously into the flanks of nude mice. Drug
treatment began on day 12 when tumors were approximately
250mg. There was no significant difference in tumor growth between
any of the treatment groups.
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significant amounts of MeP from escaping to the systemic
circulation. In contrast to the result with MeP-dR,
treatment with F-araAMP was much less effective against
tumors in which the bystander cells expressed excess
APRT activity (Figure 5). The anti-tumor activity of
F-dAdo was similar to that seen against D54 tumors in
which 10% of the cells express E. coli PNP.
Measurement of prodrug activation in subcutaneous
D54 tumors
Mice bearing D54 tumors of various compositions were
treated with 33mgkg
 1 [
3H]MeP-dR, 20mgkg
 1 [
3H]
F-dAdo or 100mgkg
 1 [
3H]F-araAMP to determine the
effect of excess APRT expression on the activation of the
three prodrugs. Tumors were removed 4h after injection
of compound and the total amount of radioactivity was
determined. Because the tritium label in the three
nucleosides is positioned on the purine base, differences
in radioactivity between the parental D54 tumors (which
do not express E. coli PNP) and D54 tumors that express
E. coli PNP reflect the amounts of F-Ade or MeP and
their metabolites generated by E. coli PNP and retained in
the tumor cells. The plasma half-life of these agents (MeP-
dR, 20min; F-dAdo, 7min; F-araAMP, 50min: reference
number 2) is such that there is very little compound still
circulating 4h after injection. The results in Table 1,
therefore, indicate that expression of excess APRT
activity in either E. coli PNP-expressing cells or in
bystander cells, does not increase the amount of F-Ade
present in tumors treated with either F-dAdo or
F-araAMP. This result is consistent with the observation
that the anti-tumor activity of these two compounds was
not enhanced in these tumors (Figures 1, 3 and 5).
However, there was a significant increase of MeP in
tumors with excess APRT activity in bystander cells vs
tumors without excess APRT activity, or tumors with
recombinant APRT in E. coli PNP-expressing cells. This
finding is consistent with the enhanced in vivo efficacy
observed with MeP-dR against this tumor xenograft
model (Figure 5), and supports the conclusion that
increasing APRT activity in bystander cells allows the
cells to more efficiently activate MeP that has diffused
from cells expressing E. coli PNP.
Measurement of prodrug activation in D54 cells in
culture
In an effort to understand the reasons that increased
expression of APRT in cells did not enhance the anti-
tumor activity of F-araAMP, F-dAdo or MeP-dR, the
activation of MeP-dR in the various cell lines was
determined in cell culture. Cells were incubated with
100mM [
3H]MeP-dR, and the amount of radioactivity in
the medium was determined at various times after the
Figure 4 Effect of low doses of F-araAMP on tumors that express
both E. coli PNP (purine nucleoside phosphorylase) and excess
human APRT (adenine phosphoribosyl transferase) in 10% of the
cells. Wild-type (parental, no E. coli PNP-expressing) D54 tumor
cells were mixed with D54 cells that had been transduced with either
E. coli PNP (circles) or both the E. coli PNP and the human APRT
(squares) so that 10% of the mixture contained transduced cells.
These 90/10 mixtures were injected subcutaneously into the flanks of
nude mice. F-araAMP treatment began on day 15 when tumors were
approximately 300mg. The activities of E. coli PNP and human
APRT in the D54/PNP tumors at the time of treatment were
9000±1900 units and 180±10 units, respectively. The activities of
E. coli PNP and human APRT in the D54/PNP/APRT tumors at the
time of treatment were 4800±650 units and 260±44 units,
respectively. The growth of tumors in mice treated with F-araAMP
was significantly different than that in vehicle-treated mice;
P valuesp0.001.
Figure 5 Effect of prodrugs on tumors that express E. coli PNP
(purine nucleoside phosphorylase) in 10% of the cells and excess
levels of human APRT (adenine phosphoribosyl transferase) in 90%
of the cells. D54 tumor cells transduced with the human APRT gene
were mixed with D54 tumor cells that had been transduced with the
E. coli PNP gene, so that 10% of the mixture contained cells that
expressed E. coli PNP and 90% of the cells expressed excess
human APRT activity. This 90/10 mixture was injected subcuta-
neously into the flanks of nude mice. Drug treatment began on day
14 when tumors were approximately 300mg. The activity of E. coli
PNP and human APRT in the tumors at the time of treatment were
11000±3600 units and 16000±2400 units, respectively. In the
6-methylpurine-20-deoxyriboside-treated mice on day 66 there were
four complete regressions and two small persistent tumors (32 and
40mg) that were not growing. The growth of tumors in mice treated
with drugs was significantly different than that in vehicle-treated
animals; P valuesp0.003 in all cases. The experiment has been
repeated with similar results.
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change in radioactivity in the medium surrounding D54
cells. In D54/PNP cells the radioactivity in the medium
decreased by 20% over a 10-h period, and in D54/PNP/
APRT cells the radioactivity had decreased by 40%.
Because the volume of the medium far exceeds the cellular
volume and because nucleobases and nucleosides are cell
permeable and nucleotides are not, the missing radio-
activity represents MeP-dR that was cleaved to MeP and
activated to MeP nucleotides in the cells. The rate of
utilization of MeP-dR in D54/PNP cells was 2.6nmol per
10
6 cells per h, which was slightly less than that in D54/
PNP/APRT cells (4.2nmol10
6 cells per h). High-pressure
liquid chromatography analysis of the medium surround-
ing D54/PNP or D54/PNP/APRT cells revealed that no
MeP-dR was present 10h after addition of MeP-dR, and
that all radioactivity in the medium was MeP. In contrast,
in wild-type D54 cells, the radioactivity in the medium at
10h was MeP-dR. This result indicated that a large
amount of the MeP formed by E. coli PNP inside tumor
cells was not activated by APRT, but instead diffused out
of the cell. Furthermore, a 70-fold enhanced expression of
APRT activity in cells expressing E. coli PNP, had only a
modest effect on the amount of MeP that was activated
in cells. Similar results were observed with F-dAdo and
F-araA (data not shown), which indicated that addition
of APRT also had only a modest effect on the amount of
F-Ade that was activated in cells.
While performing these experiments we noticed that the
utilization of F-araA was similar to that of F-dAdo.
Therefore, we directly compared the utilization of these
two agents in D54/PNP cell cultures that were prepared at
the same time. As with MeP-dR, there was no change in
the concentration of either F-dAdo or F-araA in the
medium surrounding D54 cells that did not express E. coli
PNP over the 1-h incubation period (data not shown),
which indicated that the rate of activation of these two
compounds by nucleoside kinases in the cells was very
low. However, in D54/PNP cells the concentration of
both F-araA and F-dAdo decreased rapidly (data not
shown). The rate of disappearance of F-araA from the
medium was 51nmol per h, which was only six-fold less
than the rate seen in F-dAdo (300nmol per h). Based on
the Km and Vmax values of F-dAdo and F-araA with
E. coli PNP,
2 we would expect a 2000-fold difference in
the rate of cleavage of F-araA and F-dAdo at 10mM of
each compound. Similar amounts of F-Ade metabolites
were produced in the D54/PNP cells from both F-araA
and F-dAdo (Figure 7). However, most (93%) of the
F-Ade generated from F-dAdo diffused out of cells and
was detected in the surrounding medium, whereas with
F-araA 50% of the F-Ade generated was found in the
medium. These results also indicated that excess expres-
sion of APRT activity could (at most) increase the
activation of F-araA only by a factor of 2.
Discussion
Based on the limitations inherent in first generation
‘suicide gene’ strategies for cancer therapy (poor bystan-
der killing, activity only against dividing cells and need for
Table 1 Incorporation of MeP-dR, F-dAdo or F-araA into D54 tumors
expressing E. coli PNP with and without excess APRT
Tumor MeP-dR F-dAdo
(nmoles per
gram of tissue)
F-araAMP
D54 tumors 10±74 ±21 3 ±9
10% PNP tumors 43±14 14±6 135±62
10% PNP/APRT tumors 49±23 16±8 130±63
10% PNP and 90%
APRT tumors
110±48* 15±9 114±68
Abbreviations: APRT, adenine phosphoribosyl transferase;
PNP, purine nucleoside phosphorylase.
Mice bearing D54 tumors expressing PNP and/or excess APRT
activity as shown in the table were treated with
3H-MeP-dR
(33mgkg),
3H-F-dAdo (20mgkg) or
3H-F-araAMP (100mgkg).
Tumors were removed 4h after injection of prodrug and the
radioactivity in each tumor was determined. Results are mean
plus or minus s.d. from eight mice. Two experiments of four mice
each were performed, which were in reasonable agreement.
D54 tumors are tumors in which 100% of the cells are wild-type
D54 cells; 10% PNP tumors are tumors in which 10% of the cells
express E. coli PNP; 10% PNP/APRT tumors are D54 tumors in
which 10% of the cells express both E. coli PNP and excess
APRT; 10% PNP and 90% APRT tumors are D54 tumors in
which 10% of the cells express E. coli PNP and the other 90% of
the cells express recombinant APRT. *P¼0.0018 with respect
to the result seen with 10% PNP tumors (Student’s t-test).
Figure 6 Removal of MeP-dR (6-methylpurine-20-deoxyriboside)
from medium surrounding D54, D54/PNP (purine nucleoside
phosphorylase) or D54/PNP/APRT (adenine phosphoribosyl trans-
ferase) cells. Confluent cells in T75 flasks were incubated with
100mM of
3H-MeP-dR (100nCiml
 1) in 20ml of culture volume
(2mmol total). Total number of cells in each group were 20±0.35
(D54), 14±0.1 (D54/PNP) and 19±0.4 (D54/PNP/APRT) million
cells. Two hundred microliters of medium was removed at various
times after the addition of
3H-MeP-dR and the amount of radioactivity
was determined. Results are the mean and standard deviation from
three separate incubations.
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Cancer Gene Therapyprolonged schedules of administration), a number of
laboratories have pursued E. coli PNP. E. coli PNP
mediates pronounced killing of tumor-bystander cells and
has been used in animal models to cure mice of slow-
growing tumors refractory to conventional agents.
1–6
Clinical trials of the strategy are under development in
the United States and Australia. The foundation for
optimizing E. coli PNP-based solid tumor therapy
includes an understanding of the role of purine metabo-
lism in tumor regressions by this approach. However, very
little is known regarding the importance of APRT, the
primary enzyme responsible for activating purine bases
such as F-Ade and MeP, in the anti-tumor activity of the
E. coli PNP approach to killing tumor cells. APRT could
represent a rate-limiting step for tumor cell killing or
bystander-dependent tumor regressions. The present
study was, therefore, intended to investigate the relation-
ship of APRT to in vivo tumor regression with E. coli
PNP, and the mechanism of bystander killing responsible
for anti-tumor efficacy.
The results reported here clearly indicate that addi-
tional APRT activity in tumor cells expressing E. coli
PNP does not augment the anti-tumor activity of the
overall strategy. It is not clear why excess APRT activity
in E. coli PNP-expressing tumor cells did not result in
more pronounced activation of either MeP or F-Ade,
although it is possible that the APRT reaction is limited
by the concentration of phosphoribosyl pyrophosphate
present in the tumor cells. If phosphoribosyl pyropho-
sphate were rate limiting, increasing the APRT enzyme
concentrations would not result in increased metabolism
of these agents. Cell lines were also obtained that
expressed higher APRT activity levels (36000nmol per
mg per h) than described in this manuscript; however, the
growth of these cells was impaired, which indicated that
modestly greater expression of APRT activity than used
in the current studies (6000 and 17000nmol per mg per h)
was toxic to the cells (data not shown), and suggested that
overexpression of APRT may utilize all of the phosphor-
ibosyl pyrophosphate in the cell and limit its availability
for other important metabolic reactions. It was of interest
that additional expression of APRT in bystander cells
enhanced the activity of MeP-dR, but these results do not
have practical significance, as it is not possible to
reproduce this artificial situation in clinical disease.
A similar approach to the one described here is being
pursued to enhance the use of E. coli cytosine deaminase
(CD) plus 5-fluorocytosine (F-Cyt) as a cancer gene
therapy strategy.
17 The product of CD and F-Cyt is
5-fluorouracil, which, similar to the adenine analogs
generated by E. coli PNP, is activated by a phosphor-
ibosyl transferase. A number of studies have combined
CD with uracil phosphoribosyl transferase (UPRT) in an
effort to enhance activation of 5-fluorouracil in tumor
cells. However, there have not been many reports directly
comparing the activity of CD alone with that of CD
plus UPRT. Tiraby et al.
18 provided evidence in bacterial
cells that combination of these two genes is better than
CD alone, and Adachi et al.
19 demonstrated that
treatment with two adenoviral vectors (each containing
one of the genes of interest) was superior to treatment
with an adenoviral vector expressing only CD. In the
latter study, results indicated that UPRT increased
incorporation of F-Cyt into RNA by a factor of 3,
increased the in vitro cytotoxicity of F-Cyt by about 10-
fold and enhanced the in vivo anti-tumor activity of CD.
Therefore, it appears that addition of UPRT to a CD
regimen can improve the anti-tumor activity of F-Cyt.
Erbs et al.
20 have shown that a CD/UPRT fusion gene is
superior to treatment with CD alone, but the improved
anti-tumor activity of this vector can also be explained by
a 100-fold increase in CD activity of the fusion gene.
The issue regarding E. coli PNP is not whether addition
of excess APRT activity can improve killing of cells that
express the enzyme, as all the three prodrugs effectively
cure mice of tumors in which all cells express this
recombinant transgene.
1–3 Instead, the question posed
here is whether expression of excess APRT can improve
killing of neighboring bystander cells that do not express
E. coli PNP. There are two possible mechanisms that
could account for the bystander activity observed with
E. coli PNP. First, there is an ‘immediate’ bystander effect
resulting from diffusion of MeP or F-Ade from cells
expressing E. coli PNP to neighboring cells. Second, there
may be ‘delayed’ bystander activity due to the release of
MeP or F-Ade (and/or their cytotoxic metabolites, MeP-
riboside or 2-F-adenosine) following death of cells. The
primary metabolites released from dying cells would be
MeP-riboside or 2-F-adenosine, unless these compounds
interacted with E. coli PNP, which would convert them to
Figure 7 Activation of F-dAdo (2-F-20-deoxyadenosine) and
F-araA in D54/PNP (purine nucleoside phosphorylase) cells. Con-
fluent D54/PNP cells were incubated with 10mM of
3H-F-dAdo or
3H-
F-araA in 20ml (100nCiml
 1) of culture volume (200nmol). Two
hundred miocroliter of medium was removed at various times after
the addition of the
3H-compounds and the total amount of radio-
activity in the medium was determined. In addition, the amount of
F-araA, F-dAdo or F-Ade (2-fluoroadenine) in the medium was
determined by reverse phase high-pressure liquid chromatography.
The results from these measurements were used to determine how
much F-Ade was in either the medium or the cells. Each point is the
mean±the s. d. of three measurements. This experiment has been
repeated with similar results.
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cells would not be able to enter bystander cells, but would
instead be rapidly degraded to nucleosides. If the
immediate mechanism was primarily responsible for
in vivo bystander activity observed with F-araA, then
excess expression of APRT in cells expressing E. coli PNP
could actually diminish in vivo bystander killing by
enhancing activation of adenine analogs in cells already
destined to die. On the other hand, if the delayed
mechanism was primarily responsible for the in vivo
bystander effect, expression of excess APRT together with
E. coli PNP would be expected to enhance bystander
killing by activating more of the purine base to be released
at a later time.
A delayed type bystander activity might be viewed as
more likely with MeP-dR, as MeP-riboside is much more
potent than MeP in killing tumor cells, whereas the
potency of F-adenosine is similar to F-Ade. MeP-riboside
is an excellent substrate for its initial activating enzyme,
adenosine kinase and it is possible that MeP-riboside
released from RNA of dying cells is activated in bystander
cells more efficiently than MeP. However, the increased
anti-tumor activity of MeP-dR and the enhanced activa-
tion of MeP-dR in tumors with excess APRT activity in
bystander cells, strongly suggest that augmented APRT in
bystander tumor cells leads to improved capture of MeP
in these cells shortly after its generation in vivo; that is, the
immediate bystander mechanism.
F-araAMP is curative in tumors in which 10% of cells
express E. coli PNP, which indicates that F-Ade is able to
access and kill the 90% of cells (that is, bystander) that do
not express E. coli PNP. However, the overexpression of
APRT in bystander cells paradoxically impaired anti-
tumor efficacy of F-araA. As there was a similar level of
activation of F-araA in tumors with and without excess
APRT activity in the bystander cells, this result suggested
that expression of APRT in the bystander cells may
determine the extent of tumor cell killing by limiting the
radius of diffusion of F-Ade away from its site of
generation in tumor cell foci expressing E. coli PNP.
It is curious that F-araAMP is a more robust anti-
cancer prodrug than either MeP-dR or F-dAdo, because
F-araA is a relatively poor substrate for E. coli PNP. The
catalytic efficiency of E. coli PNP with F-araA is 2000–
3000-fold less than MeP-dR or F-dAdo,
2 and in the case
of F-dAdo, the same molecule (F-Ade) is generated by
E. coli PNP. The unexpectedly strong activity of
F-araAMP in D54 tumors can be partially explained by
the ability of mice to tolerate much more F-araAMP than
either F-dAdo or MeP-dR. In addition, the plasma half-
life
2 of F-araA (50min) is substantially longer than that of
either F-dAdo (7min) or MeP-dR (20min). An additional
consideration with respect to MeP-dR activity is that MeP
is a much less potent toxin than F-Ade, because of its
poor activity as a substrate for APRT.
9 Moreover, the
maximally tolerated dose of MeP-dR is significantly
diminished in mice bearing tumors expressing E. coli
PNP.
The results presented in this work also suggest another
factor that may contribute to the robust anti-tumor
activity of F-araAMP in cells expressing E. coli PNP.
Similar amounts of F-Ade were produced and activated in
cells expressing E. coli PNP during a 1-h period,
regardless of whether the cells were treated with
F-dAdo or F-araA. This result indicates that F-araA is
cleaved by E. coli PNP and activated by APRT at a rate
similar to that observed for F-dAdo, despite a catalytic
efficiency of F-araA that is 3000-fold less than that of
F-dAdo. The reason for this better than expected cleavage
of F-araA relative to F-dAdo is not understood, but our
results indicate that the cleavage reaction in a cell
expressing high levels of E. coli PNP does not obey
classical Michaelis–Menten kinetics. In summary, super-
ior in vivo anti-tumor activity of F-araAMP may be fully
explained by (1) similar activation of F-araA and F-Ado
in tumor cells, (2) the ability to administer five times the
amount of F-araA compared F-dAdo and (3) the seven-
fold difference in plasma half-life between these two
compounds.
Our results demonstrate that improved anti-tumor
activity cannot be achieved simply by high-level coex-
pression of E. coli PNP and APRT. Furthermore,
increasing E. coli PNP activity beyond the levels
accomplished here would not enhance anti-tumor effec-
tiveness of these prodrugs, because most of the purine
analog that is created by E. coli PNP is not activated by
APRT, but diffuses into the extracellular space.
Even with F-araA, which is a relatively poor substrate
of E. coli PNP, about half of the F-Ade produced
diffuses out of the cell. Therefore, high-level expression of
E. coli PNP is not rate limiting for the activation of
F-araA, and the level of endogenous APRT is sufficient to
activate most of the F-Ade that is generated. This
finding points to prodrug delivery as the limiting
factor for effective in vivo anti-tumor activity with
prodrugs activated by E. coli PNP. Improved methods
for enhancing delivery of the various prodrugs to tumor
cells (slow release in depot form, regional administration
and so on) should be sought to augment the overall
strategy. Moreover, our results with F-araA indicate that
high substrate activity with E. coli PNP is not the most
important parameter in identifying effective prodrugs. At
the levels of enzyme expression used in our experiments
(similar to levels of enzyme activity achieved with
adenoviral vectors), prodrug characteristics such as
maximally tolerated dose and plasma half-life are much
more important predictors of overall anti-tumor effect
than cleavage rate by E. coli PNP. Improved anti-tumor
activity using E. coli PNP might therefore be accom-
plished with new prodrugs that exhibit less toxicity, higher
peak serum levels and prolonged systemic circulation.
The ideal agent would be one that is inert in normal
tissues but is only activated after contact with E. coli
PNP. ‘Designer’ nucleosides of this kind have been
reported
21,22 as a means to augment specificity in
combination with a structurally modified PNP enzyme.
However, this approach has not yet been successful in
identifying prodrug/enzyme combinations that demon-
strate better in vivo anti-tumor activity than that seen in
E. coli PNP and F-araAMP.
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